» Articles » PMID: 22864746

Therapeutic Effect of Ginsenoside Rd in Rats with TNBS-induced Recurrent Ulcerative Colitis

Overview
Journal Arch Pharm Res
Specialty Pharmacology
Date 2012 Aug 7
PMID 22864746
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Ulcerative colitis (UC) is characterized by oxidative and nitrosative stress and neutrophil infiltration. In the present study, we aimed to investigate the therapeutic effect of ginsenoside Rd (GRd) in rats with 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced recurrent UC. After UC was twice-induced by intracolonic injection of TNBS, rats were intragastrically administered different doses of GRd per day for 7 days. The colonic lesions and inflammation were evaluated both histologically and biochemically. Compared with the TNBS group, GRd treatment facilitated recovery of pathologic changes in the colon after induction of recurrent UC, as evidenced by a significant reduction of colonic weight/length ratio and macroscopic and microscopic damage scores (p < 0.01). The myeloperoxidase and inducible nitric oxide synthase activities with malonyldialdehyde and nitric oxide levels in colonic tissues were significantly decreased in the GRd group compared with those in the TNBS group (p < 0.01). GRd treatment was associated with remarkably increased superoxide dismutase and glutathione peroxidase activities. Results showed a valuable effect of GRd against TNBS-induced recurrent UC by inhibiting neutrophil infiltration and promoting the antioxidant capacity of the damaged colonic tissue.

Citing Articles

(-)-Fenchone Ameliorates TNBS-Induced Colitis in Rats via Antioxidant, Immunomodulatory, and Cytoprotective Mechanisms.

Araruna M, Alves Junior E, de Lima Serafim C, Pessoa M, de Souza Pessoa M, Alves V Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861081 PMC: 11769309. DOI: 10.3390/ph18010018.


Ameliorative effect of nodakenin in combating TNBS-induced ulcerative colitis by suppressing NFƙB-mediated NLRP3 inflammasome pathway.

Shah B, Solanki N Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):673-686.

PMID: 39042157 DOI: 10.1007/s00210-024-03304-3.


Terpenes: Modulating anti-inflammatory signaling in inflammatory bowel disease.

Rivera Rodriguez R, Johnson J Pharmacol Ther. 2023; 248:108456.

PMID: 37247693 PMC: 10527092. DOI: 10.1016/j.pharmthera.2023.108456.


Discovery and Validation of Potential Serum Biomarkers with Pro-Inflammatory and DNA Damage Activities in Ulcerative Colitis: A Comprehensive Untargeted Metabolomic Study.

Li M, Zhang R, Xin M, Xu Y, Liu S, Yu B Metabolites. 2022; 12(10).

PMID: 36295899 PMC: 9609580. DOI: 10.3390/metabo12100997.


Traditional Chinese medicine prescription Shenling BaiZhu powder to treat ulcerative colitis: Clinical evidence and potential mechanisms.

Chen J, Shen B, Jiang Z Front Pharmacol. 2022; 13:978558.

PMID: 36160392 PMC: 9494158. DOI: 10.3389/fphar.2022.978558.